Radiology

NIH-Funded Centers of Excellence and Program Project Grants

The Stanford Department of Radiology is home to four National Institutes of Health (NIH)-funded Centers of Excellence and one Program Project grant that contribute significant advances in technological, computational, biochemical, interventional and biological innovation in the imaging sciences. Through these programs, we have trained more than 500 individuals since our first center was established in 1995.

The National Center for Advanced Magnetic Resonance Technology at Stanford (CAMRT - P41; 1995)

The CAMRT led by Gary Glover, PhD, was established as a National Research Resource in 1995 as an NIH-funded center that brings together the expertise and talent of individuals from the Radiology Department's Richard M. Lucas Center for Imaging and the Electrical Engineering Department's Magnetic Resonance Systems Research Laboratory. This multidisciplinary group shares the common goals of developing innovative Magnetic Resonance Imaging and Spectroscopy (MRI/MRS) techniques for fundamental anatomic, physiologic and pathophysiologic studies, and serving the academic and scientific community through collaborations, education, and access to Center facilities and resources. The CAMRT provides support for collaborations and use of the facilities with more than 200 users from at least 15 departments. In addition, the innovative developments that emerge from the CAMRT are shared across the U.S. and internationally (5P41RR009784-17).

The In Vivo Cellular and Molecular Imaging Center at Stanford (ICMIC@Stanford - P50; 2005)

The ICMIC, led by Sanjiv Sam Gambhir, MD, PhD, initially funded in 2005, has an overall vision that emphasizes the application and extension of molecular imaging to translational research and clinical applications. While the ICMIC continues with its original goals to i) exploit molecular imaging by extracting basic information from animal models and pre-clinical studies ii) provide new information on tumor diagnosis, initiation, progression, and responses to therapy and iii) develop new imaging technologies, it has also expanded into clinical applications. Our ICMIC Developmental Fund projects include proposals from basic science cancer researchers with plans to integrate molecular imaging techniques into their programs. Our major goal is to provide the groundwork to integrate molecular imaging into translational studies and into clinical cancer applications by ensuring that basic scientists and clinician scientists collaborate on ICMIC funded projects with well-defined clinical application end goals (5P50CA114747-07)

The Center for Cancer Nanotechnology Excellence and Translation (CCNE-T - U54; 2006)

CCNE-T logoThe Center for Cancer Nanotechnology Excellence and Translation (CCNE-T), led by Sanjiv Sam Gambhir, MD, PhD, was approved for funding in 2010 and builds on the success of the CCNE-TR that was established in 2006. This new CCNE-T brings together scientists and physicians from Stanford University, University of California Berkeley/Lawrence Berkeley National Lab, University of California Los Angeles, University of Southern California and the Massachusetts Institute of Technology. Our goals with the CCNE-T build on our vision that in vitro diagnostics, used in conjunction with in vivo diagnostics, can markedly impact cancer patient management. Through use of nanotechnology we will be able to significantly advance both in vitro diagnostics through proteomic nanosensors and in vivo diagnostics through nanoparticles for molecular imaging. The CCNE-T focuses markedly on bringing nanotechnology into clinical (5U54CA151459-02).

Cancer Center for Systems Biology (CCSB - U54)

CCSB logoThe Stanford Cancer Center for Systems Biology (CCSB), led by Sylvia Plevritis, PhD, is one of twelve National Centers for Systems Biology and represents a multi-disciplinary collaboration. The Stanford CCSB aims to discover molecular mechanisms underlying cancer progression by studying cancer as a complex biological system that is driven, in part, by impaired differentiation. CCSB's overarching goal is to provide a better understanding of the differentiation and self-renewal properties of cancer that will enable us to identify molecular therapeutic targets and strategies to eradicate this disease, or at least, maintain it in a nonlethal state. Our approach integrates high-throughput experimental datasets at the genomic, transcriptomic and proteomic levels, with novel computational techniques, in order to reveal critical molecular networks that drive cancer progression. This multidisciplinary Center brings together 10 Stanford faculty from the Schools of Medicine, Engineering, and Human Sciences, with expertise ranging from molecular biology and oncology to mathematics, statistics, and computer science. Funded by the NIH/NCI Integrative Cancer Biology Program (http:icbp.stanford.edu), its mission is to promote the analysis of cancer as a complex system by merging experimental and computational methods (5U54CA149145-02).

Magnetic Resonance Imaging-Guided Cancer Interventions (MRI-GCI - P01; 2011)

The MRI-Guided Cancer Interventions Program Project, led by Kim Butts Pauly, PhD, established in 2011, is made up of 5 R01-like projects that are linked in their aims to develop and test controlled minimally invasive thermal ablation techniques for the treatment of cancers in soft-tissue, brain, prostate, and gut using MRI-guided focused ultrasound and RF ablation. The five projects have many common requirements for programmatic and infrastructure support, which have been consolidated into cores, including an engineering core to develop/monitor hardware and software, as well as improved device visualization. An in vivo study support core will assist all of the projects with post ablation assessment imaging, correlation with histology, and statistical support. The outcomes of this PPG will be 1) improved minimally-invasive treatment options, 2) an increase in the basic science understanding of tissue response to thermal treatments, and 3) advances in engineering, both hardware and software, specifically for treatment of these cancers (1P01CA159992-01).

Stanford Medicine Resources:

Footer Links: